Category Business

Audrey Duval Derveloy Named Global Head of Corporate Affairs, Joins Sanofi Executive Committee

Audrey Duval Derveloy Appointed Global Head of Corporate Affairs at Sanofi Audrey Duval Derveloy, a seasoned leader in the healthcare industry and current President of Sanofi France, has been appointed Executive Vice President and Global Head of Corporate Affairs at…

Read MoreAudrey Duval Derveloy Named Global Head of Corporate Affairs, Joins Sanofi Executive Committee

EU Approves Truqap Plus Faslodex for Advanced ER-Positive Breast Cancer Treatment

AstraZeneca’s Truqap (capivasertib) in combination with Faslodex (fulvestrant) has received approval from the European Union (EU) for treating adult patients with estrogen receptor (ER)-positive, HER2-negative locally advanced or metastatic breast cancer that harbors one or more PIK3CA, AKT1, or PTEN…

Read MoreEU Approves Truqap Plus Faslodex for Advanced ER-Positive Breast Cancer Treatment

Presentation of New SEQUOIA Study Findings: BRUKINSA® and Venetoclax in High-Risk First-Line CLL/SLL at EHA2024

BeiGene, Ltd. (NASDAQ: BGNE; HKEX: 06160; SSE: 688235), a global leader in oncology, has unveiled new findings from the SEQUOIA study of BRUKINSA® (zanubrutinib) today at EHA2024 in Madrid, Spain. The presentation highlighted results from arm D, exploring BRUKINSA in…

Read MorePresentation of New SEQUOIA Study Findings: BRUKINSA® and Venetoclax in High-Risk First-Line CLL/SLL at EHA2024

Enveda Biosciences Secures $55 Million to Boost Platform Development and Propel Multiple Candidates towards Clinical Trials

Enveda Biosciences Secures $55M to Advance AI-Driven Drug Development Enveda Biosciences, known for its pioneering use of AI in drug discovery, has announced a $55 million financing round. This round, which includes investments from new backers like Premji Invest, Lingotto…

Read MoreEnveda Biosciences Secures $55 Million to Boost Platform Development and Propel Multiple Candidates towards Clinical Trials

Scientific Debate on Defeating Aging Concludes with $10,000 Prize and Surprising Verdict, Promising New Investment Opportunities

A pivotal debate titled “How to Defeat Aging,” hosted by Open Longevity at the Foresight Institute on May 27, 2024, concluded with an unexpected outcome that shed light on the evolving landscape of rejuvenation biotechnology. The event featured Dr. Aubrey…

Read MoreScientific Debate on Defeating Aging Concludes with $10,000 Prize and Surprising Verdict, Promising New Investment Opportunities

Sibylla Biotech and MD Anderson Forge Strategic Partnership to Advance Small-Molecule Protein Degrader Development

Sibylla Biotech and The University of Texas MD Anderson Cancer Center have announced a strategic collaboration to discover and develop novel small-molecule cancer therapies called Folding Interfering Degraders (FIDs). These therapies disrupt the proper folding of target proteins, leading to…

Read MoreSibylla Biotech and MD Anderson Forge Strategic Partnership to Advance Small-Molecule Protein Degrader Development

EU Approves Roche’s Alecensa as First Adjuvant Therapy for ALK+ Early-Stage Lung Cancer

The European Commission has approved Alecensa® (alectinib) monotherapy as an adjuvant treatment for adult patients with anaplastic lymphoma kinase (ALK)-positive non-small cell lung cancer (NSCLC) who are at high risk of recurrence (Stage IB [≥4 cm]–IIIA NSCLC [7ᵗʰ edition UICC/AJCC])…

Read MoreEU Approves Roche’s Alecensa as First Adjuvant Therapy for ALK+ Early-Stage Lung Cancer

Geron’s RYTELO™ Approved by FDA for Lower-Risk MDS Treatment

Geron Corporation (Nasdaq: GERN), a biopharmaceutical company dedicated to revolutionizing blood cancer treatment, has received FDA approval for RYTELO™ (imetelstat). This approval is specifically for treating adult patients with low- to intermediate-1 risk myelodysplastic syndromes (MDS) who have transfusion-dependent anemia…

Read MoreGeron’s RYTELO™ Approved by FDA for Lower-Risk MDS Treatment

Majority of Children with Severe SMA Maintain or Gain Mobility with Genentech’s Evrysdi: 5-Year Data

Genentech, a member of the Roche Group, shared today groundbreaking 5-year findings reaffirming the lasting effectiveness and safety of Evrysdi® (risdiplam) in children diagnosed with Type 1 spinal muscular atrophy (SMA). These insights stem from the open-label extension of the…

Read MoreMajority of Children with Severe SMA Maintain or Gain Mobility with Genentech’s Evrysdi: 5-Year Data